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Abstract
MTAP is a ubiquitously expressed gene important for adenine and methionine salvage. The
gene is located at 9p21, a chromosome region often deleted in breast carcinomas, similar
to CDKN2A, a recognized tumor suppressor gene. Several research groups have shown
thatMTAP acts as a tumor suppressor, and some therapeutic approaches were proposed
based on a tumors´MTAP status. We analyzedMTAP and CDKN2A gene (RT-qPCR) and
protein (western-blotting) expression in seven breast cancer cell lines and evaluated their
promoter methylation patterns to better characterize the contribution of these genes to
breast cancer. Cytotoxicity assays with inhibitors of de novo adenine synthesis (5-FU, AZA
and MTX) afterMTAP gene knockdown showed an increased sensitivity, mainly to 5-FU.
MTAP expression was also evaluated in two groups of samples from breast cancer patients,
fresh tumors and paired normal breast tissue, and from formalin-fixed paraffin embedded
(FFPE) core breast cancer samples diagnosed as Luminal-A tumors and triple negative
breast tumors (TNBC). The difference ofMTAP expression between fresh tumors and nor-
mal tissues was not statistically significant. However,MTAP expression was significantly
higher in Luminal-A breast tumors than in TNBC, suggesting the lack of expression in more
aggressive breast tumors and the possibility of using the new approaches based onMTAP
status in TNBC.
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Introduction
Breast cancer is the most common cancer among women worldwide [1–2]. One of the alter-
ations involved in the development and progression of the disease is the loss of expression of
tumor suppressor genes [3].
The methylthioadenosine phosphorylase (MTAP) gene is located at 9p21 and is flanked by
the tumor suppressormiR-31 and the cyclin-dependent kinase inhibitor 2A (CDKN2A) gene
[4], which are approximately 100 kb away [5–9]. MTAP acts in the polyamine biosynthesis
pathway and is important to the salvage of both adenine and methionine [3].MTAP is ubiqui-
tously expressed in all normal tissues but frequently lost in tumors mainly due to a co-deletion
with CDKN2A. In normal cells, MTAP cleaves the 5’-deoxy-5’-methylthioadenosine (MTA)
substrate generated during the biosynthesis of polyamines, generating adenine and
5-methylthioribose-1-phosphate (MTR-1-P). Adenine is converted to adenosine monophos-
phate (AMP), and MTR-1-P is converted to methionine. Cells lackingMTAP are unable to sal-
vage AMP or methionine and are more sensitive to inhibitors of de novo AMP synthesis or to
methionine starvation than normal cells [10–11]. Because MTAP is expressed in all normal tis-
sues and is usually lost in tumors, Kadariya et al. [12] suggested usingMTAP deficiency to
selectively target tumor cells that areMTAP-negative. A promising therapeutic approach to
cancer was proposed in 2009 by Lubin and Lubin [13], based on the addition of MTA to the
treatment ofMTAP-negative tumors with toxic purine analogs, like 5-fluorouracil (5-FU).
Normal cells are protected from the toxic effects of purine analogs by the AMP produced from
MTA. However,MTAP-negative tumor cells are not able to produce AMP from the added
MTA, so the purine analogs are metabolized and exert their toxic effects [14].
We have previously reported a 90% frequency of concordant loss of heterozygosity (LOH)
for intragenic microsatellite markers for CDKN2A (D9S1748) andMTAP (D9S1749) [15].
These data indicated that in breast cancer cells, the co-deletion might play an important role,
as described in other types of tumors (3–9). The aim of the present study was to characterize
MTAP expression in breast cancer patients and cell lines and examine the relationship between
MTAP expression and chemo-sensitivity to inhibitors of AMP synthesis.
Materials and Methods
Ethics Statement
This research was approved by the “Comissão Nacional de Ética em Pesquisa (CONEP)”, from
the Health Division of Brazilian Government, number 251/2003. The Ethical Committee from
the Istituto Ospitalieri di Cremona (Italy) approved the use of formalin-fixed paraffin embed-
ded (FFPE) samples. Written informed consent was obtained from all patients. All of the sam-
ples were anonymized by a pathologist staff member, and none of the researchers conducting
the analysis had access to the clinico-pathological data.
Fresh tumors
Forty-six fresh primary breast tumors were obtained from 45 patients between 2009 and 2011
at the Hospital Nossa Senhora das Graças (Curitiba, Brazil). Non-compromised tissues of the
contralateral breast were obtained from ten patients who underwent simultaneous breast sym-
metrization. Histological analysis confirmed the normality of these samples. Tumor and nor-
mal samples were conserved in an RNA stabilization solution (RNAlater1, Applied
Biosystems, USA) immediately after surgery, and stored at 4°C until RNA isolation. Clinico-
pathological information of the patients are summarized in Table 1. Patients had received nei-
ther chemotherapy nor radiation prior to surgery.
MTAPGene in Breast Cancer
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Formalin fixed-paraffin embedded (FFPE) samples
ForMTAP gene expression in FFPE samples, a second group of 81 TNBC and 60 Luminal-A
breast tumors were retrospectively collected from patients who came to the medical observa-
tion facility at the Breast Care Unit, A.O. Istituti Ospitalieri di Cremona, Italy. We did not have
access to the clinico-pathological data of these patients. The histological classification of Lumi-
nal A, Luminal B, HER2 positive and TNBC tumors was based on St. Gallen guidelines [16],
Table 1. Clinico-pathological information of primary breast tumors.
Subtypes Number of patients %
IDC 35 76.09
ILC 3 6.52
Mixed 4 8.70
Othersa 4 8.70
Intrinsic Subtypes
Luminal-A 23 54.80
Luminal-B 14 33.30
HER2 + 2 4.80
TNBC 3 7.14
Not-informed 4
Lymph node metastasis
Present 21 48.84
Absent 22 51.16
Not-informed 3
Tumor grade
I 6 13.64
II 28 63.64
III 10 22.72
Not-informed 2
Tumor size
 20 mm 20 45.45
> 20 mm 24 54.55
Not-informed 02
Estrogen receptor (ER)
Positive 37 84.09
Negative 7 15.91
Not-informed 2
Progesterone receptor (PR)
Positive 38 86.36
Negative 6 13.64
Not-informed 2
HER2 ampliﬁcation
Positive 9 21.43
Negative 33 78.57
Not-informed 4
IDC, invasive ductal carcinoma; ILC, invasive lobular carcinoma; TNBC, triple negative breast cancer; mm,
millimeters.
aMucinous carcinoma, tubular-lobular carcinoma, pleomorphic carcinoma.
doi:10.1371/journal.pone.0145647.t001
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which define breast tumors according to the immunohistochemical staining of hormonal
receptors (ER and PR), HER2 expression, the Ki-67 marker and histological grade [17–18].
Cell lines and cell culture
Breast cancer cell lines MDA-MB-231, MDA-MB-435S, MDA-MB-468, MCF7, SK-BR-3,
T47-D and ZR-75-1 were obtained from the American Type Culture collection (ATCC1). Cell
line authentication was performed within the last 6 months. These cell lines were grown in
RPMI-1640 medium supplemented with 1% L-glutamine (Biowest, French) and 10% fetal
bovine serum (FBS; Sigma, EUA) at 37°C and 5% of CO2. Cell growth was evaluated in control
not transfected, in scramble transfected and in esiRNAMTAP transfected MDA-MB-435 cells
at different time points after transfection using MTS (3-(4,5-dimethylthiazol-2-yl)-5-(3-car-
boxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium) assay, following the manufacturer’s
description (Promega).
Reverse transcribed quantitative PCR (RT-qPCR) and Methylation
specific PCR (MS-PCR)
RNA from fresh tumors and normal samples were isolated using an RNAeasy1 Kit (Qiagen,
Germany). RNA from FFPE samples was isolated using High Pure RNA Paraffin Kit (Roche,
USA). RNA from cell lines was isolated using SV-Total RNA isolation system (Promega, USA).
All mRNAs were reverse-transcribed using the High Capacity cDNA Archive Kit (Applied Bio-
systems, USA). The integrity of all the RNA preparations was checked on a 1% agarose gel and
RNA concentrations were measured with a NanoDrop™ 1000 spectrophotometer (Thermo Sci-
entific, USA). Optimal primer pairs (S1 Table) were chosen, spanning splice junctions, using
PRIMER-3 (http://frodo.wi.mit.edu/cgi-bin/primer3/primer3_www.cgi) and Oligo Analyzer
software (http://www.idtdna.com/analyzer/applications/oligoanalyzer/). The specificity was
verified by detecting single-band amplicons of the PCR products. For the fresh samples, reac-
tions were performed with 15 ng of cDNA template, 2 pmol of forward and reverse primers
and 5 μl of SYBR Green PCRMaster Mix (Applied Biosystems), and a dissociation curve was
evaluated. Standard curves for each gene were included for efficiency reaction analysis, which
is necessary to quantify expression based on the comparative method (-DDCt). Samples were
then normalized using the housekeeping genes Actin (ACTB) and β-2-microglobulin (B2M).
These gene were chosen as housekeeping genes based on the TaqMan1Human Endogenous
Control Array microfluidic card (Applied Biosystems, USA). The normalized values were com-
pared with expression in the MDA-MB-231 cell line, which is used as a calibrator sample. The
data are described as fold changes in gene expression relative to the calibrator sample. Relative
MTAP expression in fresh samples was determined on a Mastercycler ep RealPlex System
(Eppendorf, Germany). Gene expression was performed using GoTaq qPCRMaster Mix (Pro-
mega, USA) in an ABI Prism 7900 Sequence Detection System (Applied Biosystems, USA).
To perform MS-PCR, genomic DNA was isolated from six breast cancer cell lines (except
SK-BR-3 cell line) using the Maxwell1 16 Cell DNA Purification Kit (Promega, USA). Geno-
mic DNA was modified with sodium bisulfite using the Epitect Bisulfite Kit (Qiagen, Germany)
according to manufacturer specifications. MS-PCR was performed in standard conditions
using GoTaq1Hot Start (Promega, USA) and 2 μl of modified DNA. By targeting the CpG
island sequence in the promoter region of theMTAP gene, specific primers recognizing meth-
ylated or non-methylated DNA were designed (S1 Table). MS-PCR products were separated
on 2.5% agarose gels. The experiment was repeated twice.
MTAPGene in Breast Cancer
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Western-blotting (WB)
Protein extracts from seven breast cancer cell lines were obtained using a lysis buffer (10 mM
Tris-HCl (pH 7.4); 150 mMNaCl, 0.1% NP-40; 5 mM EDTA; 50 mMNaF) in the presence of
protease inhibitors. Total cellular proteins (50 and 100 μg for CDKN2A and MTAP analysis,
respectively) were separated on 12% SDS-polyacrylamide gels and electro-transferred onto
nitrocellulose or polyvinylidene fluoride (PVDF) membranes (Protran, Schleicher & Schuell,
Germany). Immunoblotting was carried out with rabbit anti-human p16 (CDKN2A) (C-20)-G
polyclonal antibody, goat anti-MTAP polyclonal antibody (N-20) and rabbit anti-β-tubulin
(H-235) polyclonal antibody (dilution 1:200, 1:100 and 1:500, respectively), purchased from
Santa Cruz Biotechnology Inc. (Dallas, Texas, USA). Membranes were then reacted with sec-
ondary antibodies (dilution 1:3000 in blocking buffer, Santa Cruz Biotechnology) and devel-
oped using the ECL Kit (Amersham Biosciences, Sweden).
esiRNA transfection
Double-strand esiRNA forMTAP and a non-specific scrambled siRNA were obtained com-
mercially (Eupheria Biotech, Sigma). Fifty microliters of theMTAP-positive MDA-MB-435
cells were seeded in a 96-well culture vessel at 4.0 x 104 cells/ml the day before transfection.
Cells were transfected with esiRNA duplexes or scrambled siRNA (45 nmol each) using Lipo-
fectamine 2000 reagents (Invitrogen) according to the vendor’s protocol. MTAP expression
was determined using WB.
Wound Healing assay
The effect ofMTAP downregulation on the invasiveness of MDA-MB-435 cells was evaluated
with a wound healing assay. Cells were seeded in 24-well culture plates at 4 x 104 cells/mL and
after 24 hours were transfected with scramble siRNA orMTAP esiRNA in duplicate, as already
described. 48 hours later a wound was made along the diameter of each well and a picture was
taken. Cells were allowed to proliferate and to invade the wound for the next 96 hours and pic-
tures of the wells were taken. Using ImageJ software the wounded area uncovered by cells was
obtained for each picture, the mean of the duplicates was calculated and then expressed as per-
centage of the initial wounded area.
Cytotoxicity experiments
Seventy-two hours after esiRNA transfection, cells were treated for 72 hours with crescent con-
centrations of 5’aza-deoxycytidine (AZA), methotrexate (MTX) and 5-FU at a final concentra-
tion of 100 μM, 50 μM and 10 μM, respectively. These drugs were chosen due to their action as
inhibitors of de novo AMP synthesis. Cell proliferation was measured in a TECAN1 Infinite
200 multimode microplate reader (TECAN Group Ltd., Switzerland), using the MTS assay as
already described. These experiments were performed in triplicates and repeated twice.
Statistical analysis
RT-qPCR data had a non-normal distribution and were analyzed using the Shapiro-Wilk nor-
mality test. The Mann-Whitney U test was chosen to compare clinico-pathological and gene
expression data between the groups (fresh tumors and normal samples, TNBC and luminal-A
tumors), and a linear regression was chosen to correlate gene expression with patient’s age and
tumor size. Statistical analyses were carried out in Prism 5 version 5.04 (GraphPad Software
Inc., USA). All statistical tests were two-tailed and p values<0.05 were considered statistically
significant.
MTAPGene in Breast Cancer
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Results
MTAP expression in breast cancer samples
RelativemRNAMTAP expression value was 1.39 ± 0.75 and 1.98 ± 1.05 in fresh primary
breast tumors and normal samples, respectively. The difference was not statistically significant
(p value = 0.09). To evaluate a more homogeneous group, we analyzed Invasive Ductal Carci-
noma (IDC) samples separately (35 patients). The relative expression value was 1.32 ± 0.72 and
1.98 ± 1.05 in IDC and normal samples, respectively and this difference was not statistically sig-
nificant (p value = 0.065) (Fig 1a). For the IDC samples, no significant differences were found
between mRNAMTAP expression and the clinico-pathological parameters (axillary lymph
node metastasis, ER/PR/HER2 status, tumor grade, tumor size and age at diagnosis). When the
different intrinsic subtypes were considered, no difference in mRNAMTAP level was observed
between Luminal-A (n = 23) and Luminal-B (n = 14) groups (1.43 ± 0.68 and 1.26 ± 0.6,
respectively, p value = 0.45) (Fig 1b). Expression ofMTAPmRNA was also evaluated in FFPE
breast cancer samplesMTAPmRNA level was 1.62 times greater in Luminal-A than in TNBC,
and this difference was statistically significant (p value< 0.0001) (Fig 2).
MTAP and CDK2A status in cell lines
MTAPmRNA levels were evaluated in seven breast cancer cell lines. We also investigated the
expression of the CDKN2A gene to determine the presence or absence of a co-deletion.
CDKN2A andMTAPmRNAs were not detected in MDA-MB-231, ZR-75-I or MCF-7 cells. In
Fig 1. Scatter-plot graphics ofMTAP expression in fresh primary breast tumors. (a) IDC and normal
samples. Black line represents the median value. T, IDC tumors; NT, normal (non-tumor) samples; (number
of samples). (b) Luminal-A and Luminal-B fresh samples.
doi:10.1371/journal.pone.0145647.g001
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the other cell lines (MDA-MB-435, MDA-MB-468, SK-BR-3 and T47-D), different expression
levels of CDKN2A andMTAP were observed (Table 2).CDKN2A protein was readily detected
in MDA-MB-435, MDA-MB-468 and SK-BR-3, whereas MTAP protein was clearly detected in
only MDA-MB-435 and MDA-MB-468 cells and at a much lower extent in SK-BR-3 and
T47-D cells (Fig 3a and 3b and Table 2). The MDA-MB-435 cell line showed the strongest
MTAPmRNA and protein expression. MDA-MB-468 and SK-BR-3 cell lines showed interme-
diate mRNA expression and no protein expression, whereas the T47D cell line showed weak
mRNA expression and no protein expression. Cell lines MDA-MB-231, MCF-7 and ZR-75-I
did not show mRNA or protein expression. We observed an equal distribution ofMTAP
expression among cell lines in respect to their ER, PR and HER2 expression; indeed among the
cell lines positive to the hormonal receptors, two (MCF-7 and ZR-75-1) were negative and T-
47-D showed a weak expression. Among the hormonal receptors negative ones, two expressed
MTAP, MDA-MB-435, MDA-MB-468, and two MDA-MB-231and SKBR3 did not. We per-
formed MS-PCR in breast cancer cell lines to evaluate theMTAP promoter status. Four of the
MTAP promoters were partially methylated (MDA-MB-435, MDA-MB 468, MCF-7 and
T47-D), whereas in MDA-MB-231 and ZR-75-I cells, no methylated or unmethylated bands
could be detected (S1 Fig and Table 2).
esiRNA transfection and cytotoxicity experiments
Because MTAP levels have been shown to influence the cytotoxicity of some anticancer agents
[14],the MDA-MB-435 cell line was chosen to perform knockdown of theMTAP gene using
Fig 2. Scatter-plot graphic ofMTAP expression in FFPE breast cancer samples. Luminal-A and TNBC.
Black line represents the median value.
doi:10.1371/journal.pone.0145647.g002
Table 2. mRNA, protein andmethylation status ofCDKN2A andMTAP in the breast cancer cell lines.
RT-qPCR CDKN2A RT-qPCRMTAP WB CDKN2A WB MTAP MS-PCR MTAP
MDA-MB-231 ND ND ND ND ND
ZR-75-1 ND ND ND ND ND
MCF-7 ND ND ND ND M/U
MDA-MB-435 1.00 1.00 ++ +++ M/U
MDA-MB-468 1.49 0.46 +++ ++ M/U
SK-BR-3 0.57 0.42 + + NP
T47-D 4.46 0.19 ND + M/U
RT-qPCR, quantitative Real-Time PCR (relative data); ND, not detected (without expression); WB, western-blotting; MS-PCR, methylation speciﬁc PCR;
+, ++, +++, level of expression; NP, not performed; M/U, methylated/unmethylated.
doi:10.1371/journal.pone.0145647.t002
MTAPGene in Breast Cancer
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the esiRNA system. Transfection of esiRNA against MTAP completely knocked down MTAP
protein and no differences in cell growth and cell migration, assessed by the wound healing
assay were detected. S2 Fig). However, MTAP knockdown increased the cytotoxic activity of
5FU, MTX and Aza (Fig 4a–4c).
Discussion
Curtis and colleagues [19] discovered a high frequency ofMTAP deletions in an integrated
analysis of copy number and gene expression with two sets of almost a thousand primary
breast tumors. Nevertheless, there is a lack of information onMTAP-deficiency in primary
breast cancer [4]. In a previous study [15], we found a high rate (90%) of concordant LOH
between CDKN2A andMTAP genes in primary breast tumors. Here, we assessedMTAP
mRNA expression in a sample of fresh breast tumors and normal breast tissue, and the differ-
ence was not statistically significant (Fig 1a). In addition, we did not find any correlation
betweenMTAP expression and the clinico-pathological parameters, probably due the small
size of our sample. Miyazaki et al. [20], in a cohort of 40 osteosarcoma samples, found a 27.5%
decrease in MTAP protein expression and no correlations with the clinico-pathological param-
eters. Our results are similar to the findings of Alhebshi et al. [21], who reported MTAP protein
expression in 20 normal human skin tissue samples and 109 cutaneous squamous cell carcino-
mas and found no significant correlations with the clinico-pathological parameters. The small
size of our sample and contamination with normal cells after macro-dissection of the fresh
tumors may be responsible for the results we obtained. We studied a second group of FFPE
samples and found significantly higher expression ofMTAP in Luminal-A tumors than of
TNBC (Fig 2). Christopher et al. [7] observed that the loss or reduction of MTAP expression in
Fig 3. Western-blotting at breast cancer cell lines. (a) CDKN2A. (b)MTAP. β-tubulin protein;CDKN2A protein;MTAP protein. Numbers represent the
ratio.
doi:10.1371/journal.pone.0145647.g003
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breast tumor cells is involved in anchorage-independent growth. This process is important for
the progression of the disease, allowing the tumor to spread and metastasize. These characteris-
tics are commonly observed in the more aggressive cancers like TNBC. Crespo et al. [22] noted
the potential relevance ofMTAP as a tumor suppressor in glioblastomas becauseMTAP was
the single homozygously deleted gene at chromosome 9p21 (from 11 genes analyzed at this
region) for which they found a high correlation between copy number values and mRNA
expression levels. However, Dou et al. [23] observed an inverse correlation between cellular dif-
ferentiation andMTAP relative expression in colorectal cancer, mainly due to promoter
demethylation in more malignant tumors. Tang et al. [24] demonstrated that the tumor sup-
pressor function ofMTAP in HT1080 fibrosarcoma cells is not the same as its known enzy-
matic function.
MTAP loss can be associated with CDKN2A loss [10–12, 25], and promoter hypermethyla-
tion has been described as an alternative mechanism for the loss ofMTAP expression [26].
Here, we characterized gene expression (mRNA and protein levels) of MTAP and CDKN2A in
seven breast cancer cell lines and performed a promoter methylation analysis ofMTAP (Fig 3,
Table 2 and S1 Fig). MCF-7 and MDA-MB-231 cells were already known to beMTAP-defi-
cient [4]. Our results suggest that cell lines MDA-MB-231 and ZR-75-I harbor a co-deletion of
MTAP and CDKN2A genes because neither gene was amplified by RT-qPCR and MS-PCR. In
addition, protein expression of neither gene was detected by Western blotting. However, the
methods used cannot completely exclude this possibility. In our study, MCF-7 cells show no
Fig 4. MTAP inactivation by esiRNA transfection and cell viability after AMP inhibitors treatment. (a) Inhibition ofMTAP- cell viability by 5-FU. MTAP+
(control) andMTAP- cells were exposed to 5-FU concentrations ranging from 0–10 μM. Data are expressed as % of controls. (b) Same as (a) except MTX
doses ranging from 0–0.01 μMwere used instead of 5-FU. (c) Same as (a) except AZA doses ranging from 0–100 μMwere used instead of MTX. Mean ± SD
of two different experiments done in quintuplicate. *, p< 0.05; **, p< 0.005; ***, p< 0.0005, compared with the corresponding control.
doi:10.1371/journal.pone.0145647.g004
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expression of CDKN2A andMTAP; however. theMTAP promoter was partially methylated.
Bisogna et al. [27] also described a deletion of CDKN2A in this cell line but not a deletion of
CDKN2B or INK4A genes, which are closely located on the chromosome. Perhaps this is not a
case of co-deletion, andMTAP is not expressed in MCF-7 cells due to DNAmethylation.
T47-D cells show strong CDKN2AmRNA expression but no evidence of protein expression by
Western blotting. Bisogna et al. [27] observed DNA methylation of the CDKN2A promoter in
this cell line, which could explain the absence of protein in our study. However, the presence of
mRNA suggests post-transcriptional regulation, for example, via RNA interference. Kim et al.
[3] analyzed a set of gastric cancer cell lines and found a correlation between mRNA down-reg-
ulation and homozygous deletion ofMTAP and CKN2A because 8 of 10 cell lines expressed
both genes. However, the proteins were absent in two out of ten cell lines with a homozygous
deletion. We observed no difference in mRNAMTAP expression in respect to their ER, PR and
HER2 expressionamong the cell lines and these data partially constrast with the fact that in
FFEE triple negative samples did express higher MTAp mRNA levels. The low number of cell
lines considered can be at the basis of this discrepancy.
Hellerbrand et al. [28] showed a down-regulation ofMTAP in 15 hepatocellular carcinoma
(HCC) samples. Another study [29] demonstrated that down-regulation ofMTAP increases
MTA levels in HCC, which could be involved in HCC progression. Myiazaki et al. [20] pro-
posed that the MTAP enzyme deficiency observed in osteosarcomas was caused by genetic and
epigenetic mechanisms and that MTAP deficiency could be exploited using selective chemo-
therapy with inhibitors of de novo polyamine synthesis. Zimling, Jorgensen and Santoni-Rugiu
[30], studying MTAP immunoreactivity in 99 malignant pleural mesotheliomas (MPMs),
found that 65% of the tumors analyzed had a decreased reactivity to MTAP. They proposed
that this decreased MTAP expression, in combination with other common markers, could be a
potential diagnostic marker. As for MPMs, the decreased expression ofMTAP in TNBC (Fig 2)
could be useful as a diagnostic and therapeutic marker.
Several different approaches based on MTAP status have proposed to use inhibitors of de
novo purine synthesis and the enzyme substrate MTA to selectively kill MTAP-negative cells
[4, 11, 13, 31–33]. Our gene expression knockdown experiments support the therapeutic
approach proposed by Lubin and Lubin [13], once our data show a significantly higher sensi-
tivity of MTAP-negative cells to 5-FU (Fig 4a). Interestingly, our data show that TNBC cells
express significantly lessMTAP than the more differentiated group composed of Luminal-A
breast tumors (Fig 2), which may open the possibility of this new approach to TNBC patients
who lack the benefit of endocrine or targeted therapy that is largely used in Luminal and HER2
groups.
Conclusions
This work investigatedMTAP expression in breast cancer patients and cell lines, and examined
the relationship betweenMTAP expression and chemo-sensitivity to inhibitors of AMP syn-
thesis.MTAP was found significantly less expressed in TNBC than in Luminal-A breast
tumors. We observed that after gene knockdown,MTAP-negative cells were significantly more
sensitive to 5-FU, MTX and AZA. The observation that TNBC tumors have lower levels of
MTAP has to be corroborated in additional studies, but the observation suggests that this class
of patients could benefit from treatment with antimetabolites.
Supporting Information
S1 Fig.MTAPMS-PCR at breast cancer cell lines.M, methylated; U, unmethymated.
(PPTX)
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S2 Fig. Effect of MTAP downregulation on the proliferation and the invasiveness of
MDA-MB-435 cells. A. Western-blotting of MTAP, CDKN2A and β-Tubulin proteins at 48
and 72 hours from transfection with scramble siRNA and MTAP esiRNA. B. Proliferation of
cells untransfected, transfected with scramble siRNA and transfected with MTAP esiRNA
expressed as value of adsorbance at the wavelenght of 490 nm at different time points. C. Inva-
siveness of cells untransfected, transfected with scramble siRNA and transfected with MTAP
esiRNA expressed as percentage of the uncovered area versus the initial one at different times
from the wound.
(PPTX)
S1 Table. RT-qPCR and MS-PCR primers. Primers sequences are in the sense 5’- 3’. m, meth-
ylated; u, unmethylated.
(DOCX)
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